CD146+ Umbilical Cord Mesenchymal Stem Cells Exhibit High Immunomodulatory Activity and Therapeutic Efficacy in Septic Mice
DOI: https://doi.org/10.2147/JIR.S396088
IF: 4.5
2023-02-11
Journal of Inflammation Research
Abstract:Lin Zhang, 1, 2 Xiaoxu Zhang, 1 Yubin Liu, 2 Weiyuan Zhang, 1 Chu-Tse Wu, 2 Lisheng Wang 1, 3 1 Laboratory of Molecular Diagnosis and Regenerative Medicine, the Affiliate Hospital of Qingdao University, Qingdao, People's Republic of China; 2 Beijing Institute of Radiation Medicine, Beijing, People's Republic of China; 3 Department of Rehabilitation Sciences, School of Nursing, Jilin University, Changchun, People's Republic of China Correspondence: Lisheng Wang, Laboratory of Molecular Diagnosis and Regenerative Medicine, the Affiliate Hospital of Qingdao University, Qingdao, 266000, People's Republic of China, Email Background: Several studies have shown that MSCs can significantly improve the survival of sepsis animals. CD146+ mesenchymal stem cells (MSCs) correlate with high therapeutic potency. However, their therapeutic effect on sepsis and detail mechanisms have not been explored. Methods: The effect of CD146±MSCs on differentiation of Treg, Th1, Th17 subsets was evaluated by flow cytometry. The effects of CD146±MSCs on RAW264.7 phagocytosis and LPS-stimulated polarization were studied using a co-culture protocol. Luminex bead array and RNA sequencing were employed to determine the mechanisms of MSCs on LPS-stimulated RAW264.7. The Arg1 protein was detected by Western blot. CD146±MSCs were injected into LPS-induced sepsis mice by tail vein. The therapeutic effect was assessed by organ HE staining, T-cell subsets, cytokine in plasma, peritoneal macrophages, infiltrating monocytes subpopulations. Results: In vitro, CD146+MSCs could significantly increase the proportion of Treg cells. Co-culture with CD146+MSCs increase the phagocytic rate of RAW264.7. CD146+MSCs regulate M2-type macrophages production more rapidly. The transcript profile differences between the CD146+MSCs and CD146-MSCs groups were clustered in arginine metabolism pathways. CD146+MSCs decreased NO production and increased ARG1 expression. CD146+MSCs secreted higher level of IL15,IFNγ, VEGF and lower level of IL1β, IL8 under LPS stimuli. In vivo, The level of IL10 at 24h and CXCL1, IFNγ at 12h in CD146+MSCs group was the highest. CD146+MSCs treatment enhances the phagocytic capacity of peritoneal macrophages. CD146+MSCs also increases the ratios of CD11b+Ly6C lo reparative monocytes and CD11b+Ly6C hi inflammatory monocytes until 24h. Conclusion: Compared with CD146-MSCs, CD146+MSCs can accelerate the end of the inflammatory response and have robust anti-inflammatory effects, by increasing the Treg cells, promoting macrophage phagocytosis, enhancing the reparative macrophage, secreting more VEGF, etc. Keywords: UC-CD146±MSCs, macrophages, sepsis, anti-inflammatory Sepsis is a systemic inflammatory response syndrome caused by the invasion of pathogenic microorganisms. It is a rapidly progressive disease with a high mortality rate up to 40%, and its incidence is increasing each year, making it a prominent problem for the global medical community. 1 When pathogens disrupt the body's natural barriers to entry, the innate immune system is activated by interactions with pattern recognition receptors expressed on the cell surface, triggering an inflammatory response and the release of cytokines. 2 The early release of cytokines involves proinflammatory and anti-inflammatory cytokines, including TNFα, IL1β, IL6, IL4, and IL10. The imbalance between pro- and anti-inflammatory effects causes an amplified inflammatory cascade response. 3 Neutrophils and mononuclear macrophages arrive in large numbers at the site of the inflammatory response and release the late inflammatory factor HMGB1, 4 which further leads to tissue and vascular endothelial damage and the progression of coagulation abnormalities and organ failure. 5 Current sepsis treatment is mostly supportive, such as antibiotics, rehydration therapy, vasoactive drugs, and immunotherapy, and there are no specific sepsis treatment options that can improve the prognosis of patients. 6,7 Impaired immune function is the main pathophysiological mechanism in the development of sepsis. Focusing on the overall immune response of the body and regulating the imbalance between anti-inflammatory and proinflammatory effects will help develop an effective means to treat sepsis. MSCs are ideal effector cells for the treatment of sepsis because of their bidirectional regulation of the immune system. The mechanisms by which MSCs can treat sepsis include reducing the level of proinflammatory factors, increasing the expression of anti-inflammatory factors, inhibiting the inflammatory cascade, regulating the activity of immune cells, and redu -Abstract Truncated-
immunology